Fierce Biotech July 13, 2022
Max Bayer

FDA Commissioner Robert Califf, M.D. didn’t mince words when recently asked how the U.S. fared in terms of generating evidence for medical products.

“I mean by my standards, it’s not even good. I’d say mediocre at this point,” he said at a roundtable with the Alliance for a Stronger FDA, a lobbying group that advocates for agency funding. Califf said the U.S. does a good job developing medical products through early-phase development before hitting a wall.

“You ask the question: Do we understand what the right doses of drugs are? How to use devices? How to combine and compare choices that we have to make with medical products? I’d say we’re doing a lousy job of generating...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Medical Devices, Pharma, Pharma / Biotech
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article